Basics of Chimeric Antigen Receptor (CAR) Immunotherapy - 1st Edition - ISBN: 9780128195734

Basics of Chimeric Antigen Receptor (CAR) Immunotherapy

1st Edition

Authors: Mumtaz Balkhi
Paperback ISBN: 9780128195734
Imprint: Academic Press
Published Date: 19th July 2019
Page Count: 92
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field.

Key Features

  • Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols
  • Provides unique authority as the editor has worked directly with CARs
  • Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome
  • Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field


Academia (research and development) who work on immunotherapies, (post) graduate students in biomedical science, researchers, scientists, (post) graduate students in translational medicine

Table of Contents

  1. An introduction to CAR immunotherapy
    2. Components and design of Chimeric Antigen Receptors (CARs)
    3. scFv cloning, vectors and CAR production in laboratory for preclinical application
    4. Production of CAR-T cells for clinical application
    5. Challenges and opportunities to improve CAR-TE cell therapy


No. of pages:
© Academic Press 2020
19th July 2019
Academic Press
Paperback ISBN:

About the Author

Mumtaz Balkhi

Mumtaz Y. Balkhi, Ph.D., Chief Scientific Officer, Immunotherapeutic Lab (ITL); faculty appointments as Assistant Professor in the Hematology-Oncology Division, Department of Medicine, Tufts University School of Medicine. Assistant Professor (cooperating), Division of Biomedical Sciences, Orono Maine, USA

Affiliations and Expertise

Chief Scientific Officer, Immunotherapeutic Lab (ITL)

Ratings and Reviews